MedTrace Logo

Evaluation of Neovis® Total Multi Versus Systane® Balance on Ocular Dryness Associated With Meibomian Gland Dysfunction

NCT05191771 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-01-13

No results posted yet for this study

Summary

This study is a multicentric, comparative, randomized, investigator-blinded, in parallel groups study to demonstrate the non-inferiority of Neovis® Total Multi in comparison with Systane® Balance, in terms of improvement of stability of Tear film in patients with eye dryness associated to meibomian gland dysfunction, after 28 days of treatment.

Conditions

  • Dry Eye
  • Meibomian Gland Dysfunction

Interventions

DEVICE

Neovis Total Multi

1 drop in each eye, 4 times per day

DEVICE

Systane Balance

1 drop in each eye, 4 times per day

Sponsors & Collaborators

  • Horus Pharma

    lead INDUSTRY

Principal Investigators

  • Hoffart Louis · Vision Sud

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2022-10-31
Completion
2022-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191771 on ClinicalTrials.gov